Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of intramuscular (IM) administration of Engensis on pain in participants with painful diabetic peripheral neuropathy (DPN) in the feet and lower legs, as compared to Placebo, as a second Phase 3, well controlled study, sufficient in supporting the efficacy and safety of Engensis.


Clinical Trial Description

Overall Design VMDN-003-2 is an adaptive Phase 3, double-blind, randomized, placebo-controlled, multicenter study designed to assess the efficacy and safety of Engensis (containing the active pharmaceutical ingredient VM202) in Participants with painful DPN. Following completion of the informed consent process, Screening activities (during 45 days [from Day -52 to Day -7] prior to Day 0) will determine which Participants meet all-but-one eligibility criteria, which are assessed by an adjudication procedure, followed by completion of a 7-day eDiary prior to Day 0. Eligible participants will be enrolled and randomly assigned in a double-blind fashion and in a 1:1 ratio on Day 0 to either Engensis or Placebo. During Screening, medical history and familial cancer history, demographics, vital signs, height, body mass index (BMI), waist size, physical examination, retinal fundoscopy (by an ophthalmologist), 12-lead electrocardiogram (ECG), ultrasound of the right and left gastrocnemius muscles (to guide IM Study Injections), laboratory assessments, estimated glomerular filtration rate (eGFR), HBA1c levels, viral screening, a record of all concomitant medications and procedures, urine drug analysis, and urine pregnancy test for females of childbearing potential will be conducted. In addition, the following procedures will be conducted during Screening: Hospital Anxiety and Depression Scale (HADS), Accurate Pain Reporting (APR) and Placebo Response Reduction (PRR), Michigan Neuropathy Screening Instrument (MNSI), and cancer screening tests. During 7 days before Day 0 and randomization, Participants must complete the full Brief Pain Inventory for Diabetic Peripheral Neuropathy (BPI-DPN) on an eDiary for determining the Average Daily Pain Scores (ADPSs) for at least 5 out of the 7 days. Adverse event (AE) assessments will start upon completion of the consent process at the start of Screening. At any time prior to dosing on Day 0, Bedside Sensory Testing (BST) should be administered. Following randomization, and prior to the first IM injections of Engensis or Placebo on Day 0, the partial BPI-DPN, , and quality of life instruments will be completed. Blood will be collected for testing of selected cytokines, anti-HGF antibodies, and laboratory assessments. All Participants will receive sixteen (16) 0.5-mL IM injections of Engensis or Placebo in each calf gastrocnemius muscle at each of two Visits during two Treatment Cycles: Treatment Cycle 1 on Day 0 and Day 14, and Treatment Cycle 2 on Day 90 and Day 104. At 2 hours (± 1 hour) after completion of IM injections of Engensis or Placebo on Days 0 and 14 and Days 90 and 104, vital signs and blood draw for cytokine levels will be performed. Treatment-emergent adverse event (TEAE) assessment, including injection site reactions, will start as of randomization (Day 0) and continue throughout the study. Follow-up Study Visits will be conducted on Days 28, 60, 150, and 180 or early termination (ET). Vital signs will be recorded at all Study Visits. At the Day 180 Visit (end of study), the following assessments will be conducted: the full BPI-DPN (performed for 7 days prior to the Day 180 Visit), MNSI, BST, Patient Global Impression of Change (PGIC), and the quality of life assessments (36-item Short Form Health Survey [SF-36] and EuroQol Health Utilities Index [EQ-5D]), urine drug analysis, retinal fundoscopy, physical examination, concomitant medications and procedures, and anti-HGF antibodies. Blood will be drawn for determination of serum chemistry, lipid profile, pregnancy status, hematology, and HbA1c levels. The purpose of this study is to assess the efficacy and safety of Engensis compared to Placebo as measured by changes in the means of the Average Daily Pain Scores (ADPSs) of the full BPI-DPN, selected blood cytokines, BST, and assessments of injection site reactions, physical examination, laboratory assessments, vital signs, TEAEs, and serious adverse events (SAEs). Study and Treatment Duration: Screening will occur up to 52 days prior to Baseline (Day 0) and Participants will be followed from Day 0, the day of first Study Injections, to Day 180/ET. Visit Frequency: Consented Participants will be seen and evaluated for enrollment during Screening (up to 52 days prior to Baseline, Day 0). There are 8 visits to the Clinical Site during the study from Day 0 to Day 180 for Study Injections and follow-up. Intervention Groups and Duration: Two treatment groups of Participants (Engensis or Placebo) will be in the study for 180 days. Number of Participants (N = 152 to approximately 250): The target sample size is a minimum of 152 Participants and the maximum sample size is 250 Participants based on the proposed adaptive design analysis. The final sample size of Participants to be enrolled and evaluated will be determined by the independent Data Monitoring Committee (DMC). An interim analysis will be conducted after approximately 50% of Participants in the target sample (i.e., 76 Participants) have completed the primary efficacy endpoint at Day 180 or have withdrawn prematurely. The DMC will make a recommendation based on an unblinded (comparative) power analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04469270
Study type Interventional
Source Helixmith Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 9, 2020
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT04988321 - Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms N/A
Completed NCT00385671 - An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Phase 4
Completed NCT00159679 - Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Phase 4
Completed NCT00141401 - Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy. Phase 3
Completed NCT00553475 - Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy Phase 3
Completed NCT00381719 - Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy Phase 2
Completed NCT00539175 - Treatment of Painful Diabetic Neuropathy With Photon Stimulation N/A
Completed NCT00058968 - A Study for the Treatment of Painful Diabetic Neuropathy Phase 3
Completed NCT05029297 - Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy. Phase 3
Completed NCT02215252 - A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN) Phase 2
Completed NCT00785577 - A Study for Treatment of Pain in Patients With Diabetic Neuropathy. Phase 2
Completed NCT00858351 - Thermal Biofeedback for the Treatment of Diabetic Neuropathy N/A
Completed NCT03047278 - Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain. Phase 4
Completed NCT01628627 - Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Phase 4
Completed NCT03315598 - Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain N/A
Completed NCT01057693 - Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy Phase 3
Completed NCT01564459 - Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) Phase 2
Recruiting NCT01214590 - Preliminary Assessment of the Efficacy of the VascuActiveâ„¢ Device on Diabetic Peripheral Neuropathy N/A
Completed NCT01089556 - A Study in Painful Diabetic Neuropathy Phase 3
Completed NCT00501202 - Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). Phase 2